Trial Profile

Phase 1/2 Study of PX-866 and Cetuximab (Oncothyreon, Inc. PX-866-003)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonolisib (Primary) ; Cetuximab
Indications Colorectal cancer; Head and neck cancer
Focus Therapeutic Use
Sponsors Oncothyreon

Most Recent Events

18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
21 May 2013 85 and 83 patients have been enrolled in the colorectal cancer and head and neck cancer groups, with primary efficacy data expected later this month and by year end respectively, according to the Q1 2013 financial report for Oncothyreon.
13 May 2013 Planned End Date changed from 1 Apr 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com